MENU
Alnylam

Archives: Presentations

April 26, 2017

Final 24-Month Results from Phase 2 OLE Study of Patisiran, in Development for hATTR Amyloidosis

We reported final 24-month results from our Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis. These data were presented at the American Academy of Neurology (AAN) 2017 Annual Meeting in Boston, Massachusetts.

April 20, 2017

Pre-Clinical Data with a Combinatorial RNAi/Vaccination Therapy as a Potential Functional Cure for Chronic Hepatitis B Virus Infection

We presented pre-clinical data with a combinatorial RNAi/vaccination therapy for Hepatitis B Virus (HBV) infection at The EASL International Liver Congress, held April 19-23 in Amsterdam, The Netherlands. Treatment with the combination therapy led to an HBV-specific immune response and sustained loss of HBsAg in a mouse model of chronic HBV infection. We believe this Read More

March 23, 2017

Results of Survey Assessing Utility and User Experience with Alnylam Act Reported at Annual Clinical Genetics Meeting

We presented results from a survey evaluating the utility and user experience of an independent genetic testing and counseling service for hereditary ATTR (hATTR) amyloidosis that is supported by Alnylam – Alnylam Act – at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, held March 21 – 25 in Phoenix, Read More

February 2, 2017

New Exploratory Analysis Results from Fitusiran, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

We reported new results from an exploratory analysis of our Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B with or without inhibitors at the 10th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) held February 1 – 3, 2017 in Paris, France.

December 16, 2016

R&D Day 2016

On December 16, 2016, we hosted our fourth consecutive R&D Day in New York City. Alnylam management and key opinion leaders discussed our most advanced clinical programs, reviewing all the latest data for patisiran, fitusiran and givosiran.

December 5, 2016

Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

We reported new results from Part C of our Phase 1/2 clinical study of ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases, at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California.

December 3, 2016

Interim Clinical Results from Fitusiran, an investigational RNAi therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

We reported positive interim results from our Phase 1 study of fitusiran in patients with hemophilia with inhibitors as well as from our Phase 2 open-label extension (OLE) study in hemophilia patients without inhibitors at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California.

December 3, 2016

Initial Evidence of Clinical Activity Shown with Givosiran (ALN-AS1) in Acute Intermittent Porphyria Patients with Recurrent Attacks

We reported positive initial results from Cohorts 1 and 2 in Part C of our Phase 1 study with givosiran (gi-VOH-si-ran), the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias.  These results were presented at the 58th Annual Meeting of the Read More

November 11, 2016

Interim Results from EXPLORE Natural History Study for Acute Hepatic Porphyrias

We reported interim results from our ongoing EXPLORE study, a multinational, prospective, observational study aimed at characterizing the natural history and clinical management of patients with acute hepatic porphyrias (AHP) who experience recurrent attacks or receive prophylactic treatment to prevent attacks.  Results from 112 patients, of which 104 have acute intermittent porphyria (AIP), showed a Read More

September 28, 2016

Clinical Data from ALN-AAT and Non-Clinical Research Demonstrating Continued RNAi Platform Optimization and Leadership in the Field

We presented clinical and non-clinical data in a series of posters and oral presentations at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 25 – 28, 2016 in Montreal, Quebec.